Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?

While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.